Psychedelics may influence inflammation, metabolism, immunity, and aging pathways beyond mental health through serotonin signaling and neuroimmune effects

Psychedelics may affect the body as well as the mind by interacting with serotonin receptors, immune signaling, inflammation, metabolism, and stress-response systems. Interest is shifting from purely psychiatric outcomes toward whole-body effects that could matter for chronic disease, recovery, and healthy aging. Psilocybin, LSD, DMT, MDMA, and ketamine are discussed in relation to neuroplasticity, autonomic regulation, and possible anti-inflammatory or immunomodulatory effects. Preclinical findings and early human signals suggest these compounds could influence pain, gut-brain communication, and cellular pathways tied to resilience, but the evidence remains uneven across substances and indications. Mechanisms likely involve cross-talk between the nervous, endocrine, and immune systems rather than a single reset switch. Clinical relevance depends on dose, context, safety, and much stronger trials, especially because intriguing biological signals do not yet establish durable medical benefit outside mental health settings.